250 related articles for article (PubMed ID: 33119478)
21. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.
Brouwers AH; Mulders PF; de Mulder PH; van den Broek WJ; Buijs WC; Mala C; Joosten FB; Oosterwijk E; Boerman OC; Corstens FH; Oyen WJ
J Clin Oncol; 2005 Sep; 23(27):6540-8. PubMed ID: 16170161
[TBL] [Abstract][Full Text] [Related]
22. Radioimmunoscintigraphy and Pretreatment Dosimetry of
Pandit-Taskar N; Grkovski M; Zanzonico PB; Pentlow KS; Modak S; Kramer K; Humm JL
J Nucl Med; 2023 Jun; 64(6):946-950. PubMed ID: 36759197
[TBL] [Abstract][Full Text] [Related]
23. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
[TBL] [Abstract][Full Text] [Related]
24. CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
Hartlapp I; Hartrampf PE; Serfling SE; Wild V; Weich A; Rasche L; Roth S; Rosenwald A; Mihatsch PW; Hendricks A; Wiegering A; Wiegering V; Hänscheid H; Schirbel A; Werner RA; Buck AK; Wester HJ; Einsele H; Kunzmann V; Lapa C; Kortüm KM
J Nucl Med; 2023 Sep; 64(9):1424-1430. PubMed ID: 37348915
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
26. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
Boudousq V; Bobyk L; Busson M; Garambois V; Jarlier M; Charalambatou P; Pèlegrin A; Paillas S; Chouin N; Quenet F; Maquaire P; Torgue J; Navarro-Teulon I; Pouget JP
PLoS One; 2013; 8(7):e69613. PubMed ID: 23922757
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Cancer Sci; 2003 Jul; 94(7):650-4. PubMed ID: 12841877
[TBL] [Abstract][Full Text] [Related]
28. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
[TBL] [Abstract][Full Text] [Related]
31. Survival and toxicity following sequential multimodality treatment including whole abdominopelvic radiotherapy for patients with desmoplastic small round cell tumor.
Osborne EM; Briere TM; Hayes-Jordan A; Levy LB; Huh WW; Mahajan A; Anderson P; McAleer MF
Radiother Oncol; 2016 Apr; 119(1):40-4. PubMed ID: 26527430
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor.
Espinosa-Cotton M; Cheung NV
Front Oncol; 2021; 11():772862. PubMed ID: 34869013
[TBL] [Abstract][Full Text] [Related]
34. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.
Aloj L; D'Ambrosio L; Aurilio M; Morisco A; Frigeri F; Caraco' C; Di Gennaro F; Capobianco G; Giovannoni L; Menssen HD; Neri D; Pinto A; Lastoria S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):867-77. PubMed ID: 24435772
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series.
Verret B; Honore C; Dumont S; Terrier P; Adam J; Cavalcanti A; Sourrouille I; Klausner G; Ahlenc-Gelas M; Kiavue N; Domitrescu G; El Amarti L; Mir O; Le Cesne A
Anticancer Drugs; 2017 Jan; 28(1):116-119. PubMed ID: 27782906
[TBL] [Abstract][Full Text] [Related]
37. Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Stiles ZE; Murphy AJ; Anghelescu DL; Brown CL; Davidoff AM; Dickson PV; Glazer ES; Bishop MW; Furman WL; Pappo AS; Lucas JT; Deneve JL
Ann Surg Oncol; 2020 Jan; 27(1):171-178. PubMed ID: 30963398
[TBL] [Abstract][Full Text] [Related]
38. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
39. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
40. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
